TY  - JOUR
AU  - Hamacher, Rainer
AU  - Lanzafame, Helena
AU  - Mavroeidi, Ilektra A
AU  - Pabst, Kim M
AU  - Kessler, Lukas
AU  - Cheung, Phyllis F
AU  - Bauer, Sebastian
AU  - Herrmann, Ken
AU  - Schildhaus, Hans-Ulrich
AU  - Siveke, Jens
AU  - Fendler, Wolfgang P
TI  - Fibroblast Activation Protein Inhibitor Theranostics: The Case for Use in Sarcoma.
JO  - PET clinics
VL  - 18
IS  - 3
SN  - 1556-8598
CY  - Orlando, Fla. [u.a.]
PB  - Elsevier
M1  - DKFZ-2023-00660
SP  - 361-367
PY  - 2023
N1  - 2023 Jul;18(3):361-367
AB  - The theranostic use of fibroblast activation protein inhibitors (FAPIs) is a novel approach in oncology. Sarcomas are a heterogenous group of rare malignant tumors. Prognosis remains poor in advanced/metastatic disease due to limited therapeutic options. Sarcoma frequently demonstrate high expression of fibroblast activation protein alpha on the tumor cells themselves, in contrast to other solid tumors, where it is mainly expressed on cancer-associated fibroblasts. Consequently, high in vivo uptake of FAPI in PET is observed in sarcoma. Moreover, retrospective case reports and series demonstrated feasibility of FAPI radioligand therapy with signs of tumor response.
KW  - FAP-Alpha (Other)
KW  - FAPI (Other)
KW  - Oncology (Other)
KW  - PET (Other)
KW  - Radioligand (Other)
KW  - Sarcoma (Other)
KW  - Therapy (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36997366
DO  - DOI:10.1016/j.cpet.2023.02.008
UR  - https://inrepo02.dkfz.de/record/274583
ER  -